Biotech Values

[DewDiligence]

Starton Therapeutics, a cancer drug-delivery company, goes_public_via_SPAC_merger with HWEL:

https://finance.yahoo.com/news/starton-therapeutics-inc-healthwell-acquisition-110000086.html

Proceeds from the business combination are expected to be used, among other things, to support Starton’s research and clinical development programs, including:

• STAR-LLD in MM is in development for new MM indications in intolerant patients and achievement of superiority versus oral lenalidomide [Revlimid] in maintenance treatment of MM. The STAR-LLD delivery system is expected to expand use following discontinuations, dose reductions and treatment by reducing area under the curve (AUC) by more than 50% and a 90% lower CMax. STAR-LLD is in development in two continuous delivery systems: subcutaneous and transdermal.

• STAR-LLD in CLL is being developed in multiple indications to establish the only immunomodulatory drug (IMiD) approved for CLL. STAR-LLD is in development in two continuous delivery systems: subcutaneous and transdermal.

• STAR-OLZ in chemotherapy-induced nausea and vomiting (CINV) is a 5-day transdermal patch in development for CINV and will be the first product to be evaluated for total control, becoming the first product with a no-nausea primary indication.